NCT04323943

Brief Summary

Approximately 20% of stroke survivors have difficulties to dorsiflex the ankle and clear the ground during walking. This impairment, termed as "foot drop", is caused by an association of weak dorsiflexors and increased spasticity and stiffness of the plantar-flexors. As a consequence, walking performances are reduced and energy cost of walking is deteriorated. This may increase performance fatigability, as the locomotion will be realized at a higher percentage of the subjects' capacities. In order to overcome these issues, different treatments are proposed. One of the most conventional solutions are the use of ankle foot orthosis (AFO) and it is the most commonly prescribed device used to compensate for "foot drop". There is a very large choice of AFO on the market which can be proposed to patients with foot drop. The aim of this study is thus to assess the mechanical effects of using a manufactured carbon AFO in by comparison to a custom-made thermo-plastic AFO on walking capacity (distance and energy cost), fatigue and "foot drop" control throughout the gait phase in patients with hemiparetic stroke.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 19, 2020

Completed
8 days until next milestone

First Posted

Study publicly available on registry

March 27, 2020

Completed
5 months until next milestone

Study Start

First participant enrolled

September 7, 2020

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 23, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 23, 2021

Completed
Last Updated

January 11, 2022

Status Verified

January 1, 2022

Enrollment Period

1.2 years

First QC Date

March 19, 2020

Last Update Submit

January 10, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Distance walked during the 6 Minute Walk Test (6MWT)

    Patient will performed three experimental session (14 days between each session) during wich the primary outcome will be assessed : one session while walking with C-AFO, one session while walking with CM-AFO, and one session while walking without AFO (randomized order). 6 Minute Walk Test is a beneficial tool to evaluate walking endurance in patients with poststroke hemiparesis

    Day : 14

Secondary Outcomes (7)

  • Energy cost

    Day : 14

  • Muscular activity

    Day: 14

  • Angle

    Day : 14

  • Perceived fatigue

    Day : 14

  • Power

    Day : 14

  • +2 more secondary outcomes

Study Arms (3)

Carbon-AFO (C-AFO)

EXPERIMENTAL

Manufactured carbon ankle foot orthosis (C-AFO) Sprystep (Thuasne) will be provided to patients. A familiarization with C-AFO will be performed before doing the tests.

Device: Ankle Foot orthosis (AFO)

Custom-made thermo-plastic orthosis (CM-AFO)

ACTIVE COMPARATOR

Own custom-made thermo-plastic orthosis (CM-AFO) of patients. A familiarization will be performed also before doing the tests.

Device: Ankle Foot orthosis (AFO)

Without orthosis (NO)

NO INTERVENTION

No orthosis - patient will wear only their shoes

Interventions

The experimental protocol will require 4 visits: one inclusion visit and 3 visits for evaluations. Each visit corresponds to one condition: C-AFO, CM-AFO or NO (according to a random order). Visit #1 will consist in a clinical evaluation and a familiarization session with the measuring devices and methodologies used in visit#2 #3 and #4. During #2, #3 and #4 visits (14 days between each session), the subject will perform with C-AFO, CM-AFO or NO according to the random order : * 5 x 15m overground at a comfortable walking speed (CWS) where EMG, ground reaction force and kinematics will be measured * 6MWT where energy cost will be measured * 5 x 15m overground (immediately after the 6MWT) at a comfortable walking speed

Also known as: Sprystep (Thuasne)
Carbon-AFO (C-AFO)Custom-made thermo-plastic orthosis (CM-AFO)

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Hemiparetic patients, walking with CM-AFO
  • Diagnosis of a first stroke since at least 6 months with medical conditions of stroke known, treatment proposed, cardio-vascular and neurological state stabilized
  • Foot drop observed during the swing phase of gait, requiring the use of a custom-made plastic orthosis that has been used for at least 3 months and used for less than 2 years
  • Muscle spasticity not higher than grade 3 according to the Modified Ashworth Scale
  • Sufficient motor ability and endurance to ambulate at least 15 m independently without AFO
  • Patient who signed a consent
  • Patients affiliated or entitled to a social security system.

You may not qualify if:

  • Patients who did not have brain MRI imaging after their stroke to confirm the diagnosis of stroke,
  • Patients with an associated cerebellar syndrome,
  • Patients with clinical brainstem involvement (cranial pair deficit),
  • Patients with a neurological history other than stroke that has an impact on walking,
  • Patients with unstable cardiovascular or respiratory disorders likely to induce gait disorders that may influence the performance of the tests to a greater extent than in the case of vascular hemiplegics,
  • Patients with alcohol or drug dependence,
  • Patients with psychiatric illness, cognitive impairment, uncontrolled disease/epilepsy, malignant pathology, renal impairment, unstable or decompensated diabetes, severe,
  • Patients with a history of associated disabling systemic disease,
  • Patients who refused to sign the written consent,
  • Patients with a current pregnancy,
  • Patients under court protection.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chu Saint Etienne

Saint-Etienne, 42055, France

Location

MeSH Terms

Conditions

Gait Disorders, Neurologic

Condition Hierarchy (Ancestors)

Neurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Paul Calmels, MD,PhD

    CHU Saint Etienne, Bellevue

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Model Details: Randomized, cross-over, open labelled, monocentric, controlled trial
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 19, 2020

First Posted

March 27, 2020

Study Start

September 7, 2020

Primary Completion

November 23, 2021

Study Completion

November 23, 2021

Last Updated

January 11, 2022

Record last verified: 2022-01

Locations